FDA names MB-101 US orphan drug for certain types of glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…
Latest news & perspectives
Approval sought of relacorilant for platinum-resistant ovarian cancer
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
FDA OKs label changes to boost CAR T-cell therapy use for cancer
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
